ASNR Study Groups

ASNR members may join any of our Study Groups when joining or renewing membership. Contact for more information.

Co-Chairs: Tammie Benzinger, MD, PhD; Clifford Jack, MD
Vice Chair: Petrice Cogswell, MD, PhD
This group was created to facilitate the exchange of information in the field of Alzheimer’s Disease and Dementia, with a specific interest in sharing information about the diagnosis, treatment, and research of amyloid-related imaging abnormalities (ARIA).

Co-Chairs: Bruce Wasserman, MD; David Saloner, MD
The goal of this study group is to advance our understanding of cerebrovascular diseases by developing and support vessel wall imaging protocols and clinical/translational studies. Objectives include:

  • Develop uniform protocols for clinical implementation and reimbursement.
  • Stimulate research in the field, including multicenter investigations of the pathophysiology and risk factors of neurovascular disease.
  • Attract people with similar interests in vessel wall imaging from around the world.
  • Promote education and teaching mechanisms in the field, and present a unified voice for achieving vendor support for protocol development.

Co-Chairs: Christopher Whitlow, MD; Jason Druzgal, MD
The goal of this study group is to facilitate the exchange of information and knowledge amongst experts and foster collaborative research in functional and diffusion MRI.

Co-Chairs: Ramon Barajas Jr., MD; Rivka Colen, MD; Whitney Pope, MD, PhD
This study group focuses on the application of imaging-genomics to primary and metastatic brain tumors, attempting to identify further areas of exploration where understanding the relationship between imaging data and tumor molecular features has potential in achieving optimally personalized medicine. Objectives include:

  • Explore the relationship between molecular markers of malignancy and qualitative and quantitative imaging features of brain tumors.
  • Understand the potential and limitations of genomic-imaging correlates for assessing tumor biology in patients with brain tumors.
  • Leverage Imaging-Genomic correlates to improve clinical decision making at the individual patient level and to improve patient selection for multicenter drug trials.